Alembic Pharma shines on getting US FDA’s nod to market generic aripiprazole in multiple strengths

29 Apr 2015 Evaluate

Alembic Pharmaceuticals is currently trading at Rs. 481.30, up by 31.00 points or 6.88% from its previous closing of Rs. 450.30 on the BSE.

The scrip opened at Rs. 474.00 and has touched a high and low of Rs. 495.55 and Rs. 467.95 respectively. So far 70000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 508.70 on 22-Apr-2015 and a 52 week low of Rs. 228.00 on 19-May-2014.

Last one week high and low of the scrip stood at Rs. 508.70 and Rs. 443.00 respectively. The current market cap of the company is Rs. 8925.29 crore.

The promoters holding in the company stood at 74.13% while Institutions and Non-Institutions held 11.94% and 13.94% respectively.

Alembic Pharmaceuticals has received US Food and Drug Administration (US FDA) approval to market generic aripiprazole in multiple strengths and dosage forms. Generic aripiprazole is an atypical antipsychotic drug approved to treat schizophrenia and bipolar disorder.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907. The company manufactures and markets generic pharmaceuticals products all over the world.

 

Alembic Pharma Share Price

899.90 -2.30 (-0.25%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×